Red light therapy, also known as photobiomodulation, is increasingly marketed for erectile dysfunction, but does it actually work? This non-invasive treatment uses specific wavelengths of red and near-infrared light to stimulate cellular processes, with proponents suggesting it may improve blood flow and tissue health in the penis. Whilst preliminary research is intriguing, the evidence base remains limited and experimental. Red light therapy is not endorsed by NICE, the NHS, or other UK clinical guideline bodies for erectile dysfunction. Men experiencing ED should consult their GP to discuss proven, evidence-based treatments and to rule out underlying health conditions before considering experimental therapies.

What Is Red Light Therapy and How Does It Work?

Red light therapy, also known as photobiomodulation or low-level light therapy (LLLT), is a non-invasive treatment that uses specific wavelengths of red and near-infrared light to stimulate cellular processes. The therapy typically employs wavelengths in the approximate range of 600 to 1,000 nanometres, which can penetrate the skin and underlying tissues. Photobiomodulation is non-ionising and, when used within recommended parameters, is not intended to cause significant tissue heating, although some perceptible warmth may occur.

The proposed mechanism of action centres on the interaction between photons and mitochondria, the energy-producing structures within cells. It is hypothesised that when red or near-infrared light is absorbed by chromophores in the mitochondria—particularly an enzyme called cytochrome c oxidase—it may enhance adenosine triphosphate (ATP) production, the primary energy currency of cells. This increased cellular energy is thought to promote tissue repair, reduce inflammation, and improve blood flow by stimulating nitric oxide release, a key molecule in vascular function. These mechanisms remain under investigation and require further validation in robust clinical studies.

In the context of erectile dysfunction (ED), the rationale for red light therapy relates to its potential effects on vascular health and tissue regeneration. Erectile function depends heavily on adequate blood flow to the penile tissues and the health of the endothelium (the inner lining of blood vessels). Proponents suggest that red light therapy may improve endothelial function, enhance nitric oxide availability, and potentially support nerve regeneration, all of which are relevant to erectile function. However, evidence for nerve regeneration in humans is largely speculative and based on preclinical data.

Devices for red light therapy range from handheld units to larger panels, and some are marketed specifically for sexual health applications. Any device claiming to treat erectile dysfunction is a medical device and should carry appropriate UKCA marking to demonstrate compliance with UK safety and performance regulations. Patients should avoid unregulated products. Treatment protocols vary considerably in terms of irradiance (power density, measured in mW/cm²), energy density (dose, measured in J/cm²), distance from the skin, session duration (typically 10–20 minutes), and frequency (ranging from daily to several times per week). These dosing parameters are critical to outcomes but are not yet standardised. It is important to note that there is currently no NICE guidance endorsing red light therapy for erectile dysfunction, and the MHRA does not set clinical treatment protocols.

Evidence and Research on Red Light Therapy for ED

The evidence base for red light therapy in treating erectile dysfunction remains limited and preliminary. Most available research consists of small-scale studies, animal models, and mechanistic investigations rather than large, robust, sham-controlled randomised controlled trials that would be required to establish clinical efficacy and safety.

A small number of human pilot studies have explored photobiomodulation for ED with mixed results. Some have reported improvements in erectile function scores and patient-reported outcomes following red light therapy protocols, particularly in men with vasculogenic ED (erectile dysfunction caused by impaired blood flow). These studies typically measure outcomes using validated tools such as the International Index of Erectile Function (IIEF) questionnaire. However, significant heterogeneity exists in device type, wavelength, irradiance, pulse structure, energy density, and treatment schedules, making it difficult to compare findings or draw firm conclusions. The potential for placebo effects in sexual medicine is substantial, underscoring the need for well-designed sham-controlled trials with long-term follow-up.

Animal studies have provided some mechanistic support, demonstrating that low-level light therapy may improve penile blood flow, reduce oxidative stress, and support endothelial function in laboratory models. Research in rats has shown increased smooth muscle content and improved erectile responses following photobiomodulation treatment. However, translating these findings to human clinical practice requires caution, as animal models do not always predict human responses accurately.

It is also important to distinguish photobiomodulation from low-intensity extracorporeal shockwave therapy (Li-ESWT), which is a different modality sometimes investigated for ED. The two should not be confused.

Critically, red light therapy is not endorsed by NICE, the NHS, or other major UK clinical guideline bodies as a treatment for erectile dysfunction. According to NICE Clinical Knowledge Summaries (CKS) on Erectile Dysfunction and NHS guidance, photobiomodulation is not included in standard ED management pathways. There is insufficient high-quality evidence to determine its effectiveness, optimal dosing parameters, or long-term outcomes. Red light therapy for ED should be considered experimental pending robust sham-controlled randomised controlled trials with adequate follow-up.

Patients considering red light therapy should be aware that while preliminary research is intriguing, it does not yet constitute robust clinical evidence. Men experiencing erectile dysfunction should discuss conventional, evidence-based treatments with their GP or a specialist before pursuing experimental therapies.

Safety, Side Effects and What to Expect

Red light therapy is generally considered safe and well-tolerated when used appropriately and according to manufacturer instructions, with a low risk of adverse effects. Photobiomodulation is non-ionising and is not known to cause DNA damage; however, long-term safety data for genital application are limited, and caution is advised.

Reported side effects are typically mild and transient. Some users may experience temporary skin warmth, mild redness, or slight discomfort at the treatment site, which usually resolves quickly after the session ends. Patients should discontinue use if excessive warmth, pain, or skin changes occur.

Eye safety is an important consideration. Near-infrared light can be hazardous to the retina, and the beam may be invisible. Direct exposure of the eyes to bright red or near-infrared light should be avoided, and appropriate protective eyewear should be used as per the device manufacturer's guidance.

Patients should also avoid exposing the scrotum or testicles to red light therapy devices, particularly high-power or close-proximity units, due to potential concerns about heat effects on fertility. The therapy should not be used on broken skin, active infections, or suspicious skin lesions; medical advice should be sought first in these circumstances.

Individuals with photosensitivity disorders, those taking photosensitising medications, or people with active skin conditions in the treatment area should consult a healthcare professional before use. There are no known serious systemic side effects when devices are used according to guidelines, but the long-term safety profile has not been extensively studied in large populations.

If considering red light therapy, patients should be aware that results are not immediate or guaranteed. Proponents typically suggest that multiple sessions over several weeks or months may be needed before any potential benefits become apparent. Response rates appear to vary considerably between individuals, and there is no reliable way to predict who might benefit.

When to seek medical advice: Men experiencing erectile dysfunction should consult their GP before pursuing any treatment, including red light therapy. ED can be an early warning sign of cardiovascular disease, diabetes, or other serious health conditions. A proper medical assessment can identify underlying causes and ensure appropriate management.

Seek urgent medical attention if you experience:

• Priapism (a painful erection lasting more than four hours) — this is a medical emergency

• Erectile dysfunction following pelvic or penile trauma

• ED associated with chest pain, angina, or symptoms on exertion (may indicate cardiovascular disease)

• ED with new neurological symptoms (e.g., weakness, numbness, loss of bladder or bowel control)

• Penile curvature with pain (may indicate Peyronie's disease and warrants GP or urology review)

Patients are encouraged to report any suspected adverse effects or problems with medical devices via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk.

Other Treatment Options for Erectile Dysfunction

Evidence-based treatments for erectile dysfunction are widely available through the NHS and have been extensively studied for safety and efficacy. NICE Clinical Knowledge Summaries (CKS) on Erectile Dysfunction recommend a stepwise approach to ED management, beginning with lifestyle modifications and progressing to pharmacological and other interventions as needed.

Lifestyle modifications form the foundation of ED management and can significantly improve erectile function in many men. These include:

• Weight loss and regular physical activity (particularly aerobic exercise)

• Smoking cessation, as tobacco use damages blood vessels

• Reducing alcohol consumption to moderate levels

• Managing cardiovascular risk factors such as hypertension, high cholesterol, and diabetes

• Addressing psychological factors including stress, anxiety, and relationship issues

Phosphodiesterase type 5 (PDE5) inhibitors are the first-line pharmacological treatment for ED. These medications—including sildenafil (Viagra), tadalafil (Cialis), vardenafil, and avanafil (Spedra)—work by enhancing the effects of nitric oxide, improving blood flow to the penis during sexual stimulation. They are effective in approximately 70% of men with ED. Common side effects include headache, facial flushing, indigestion, and nasal congestion.

Important contraindications and cautions (as detailed in the British National Formulary (BNF) and Summaries of Product Characteristics (SmPCs) available via the electronic Medicines Compendium (eMC)):

• PDE5 inhibitors are contraindicated in men taking nitrate medications for angina or chest pain

• They are also contraindicated with riociguat (a guanylate cyclase stimulator used for pulmonary hypertension)

• Caution is required in men taking alpha-blockers for prostate symptoms or hypertension, due to the risk of hypotension

• Men with unstable cardiovascular disease should be assessed for fitness for sexual activity before starting treatment

PDE5 inhibitors are available on-demand (taken before sexual activity) or, in the case of low-dose tadalafil, as a daily option. Patients should use NHS or UK-regulated sources and avoid purchasing unregulated ED medicines online, which may be counterfeit or unsafe.

For men who do not respond to oral medications or cannot take them, second-line treatments include:

• Intracavernosal injections (alprostadil) directly into the penis

• Intraurethral alprostadil (MUSE) pellets

• Vacuum erection devices (VEDs), which are non-invasive mechanical aids

• Penile prosthesis surgery for refractory cases

Testosterone replacement therapy may be considered in men with confirmed hypogonadism (low testosterone), following appropriate assessment including repeat morning testosterone measurements and endocrine evaluation. Testosterone therapy is not a first-line treatment for ED in men with normal testosterone levels.

Psychological interventions, including cognitive behavioural therapy (CBT) and psychosexual counselling, are particularly valuable when ED has a psychological component or when relationship factors contribute to the problem. These may be used alone or in combination with medical treatments.

Referral to specialist services (urology, endocrinology, or psychosexual services) is recommended in the following circumstances, as outlined in NICE CKS:

• Failure to respond to first-line oral therapy

• Suspected endocrine disorder (e.g., hypogonadism, hyperprolactinaemia)

• Peyronie's disease (penile curvature)

• ED following pelvic surgery, radiotherapy, or trauma

• Complex psychological or relationship issues requiring specialist input

Men experiencing ED should consult their GP for a comprehensive assessment, which typically includes medical history, physical examination, and relevant blood tests (such as glucose, lipids, and testosterone levels). This evaluation can identify treatable underlying conditions and guide appropriate, evidence-based management tailored to individual circumstances.

Frequently Asked Questions